Origin and prognostic value of circulating KRAS mutations in lung cancer patients.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Letters

• Publication date

  2007-09-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CANLET.2007.03.008PMID 17449174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell-free DNA concentration in pleural fluid and serum: quantitative approach and potential prognostic factor in patients with cancer and pleural effusions.

  2006cited by this paper
• K-ras mutations in non-small-cell lung carcinoma: a review.

  2006cited by this paper
• Evolution of intratumoral genetic heterogeneity during colorectal cancer progression.

  2005cited by this paper
• Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?

  2005cited by this paper
• Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer.

  2005cited by this paper
• Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays.

  2005cited by this paper
• Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?

  2005cited by this paper
• Detection of circulating cancer cells with K-ras oncogene using membrane array.

  2005cited by this paper
• Mutant DNA in Plasma of Lung Cancer Patients: Potential for Monitoring Response to Therapy

  2004cited by this paper
• Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

  2004cited by this paper
• Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA.

  2004cited by this paper
• Comment on "Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-call lung cancer patients" (Cancer Letters 2003;193:207-216).

  2004cited by this paper
• Quantification of free circulating DNA as a diagnostic marker in lung cancer.

  2003cited by this paper
• Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients

  2003cited by this paper
• Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.

  2003cited by this paper
• Circulating DNA: a new diagnostic gold mine?

  2002cited by this paper
• Prognostic factors in non-small cell lung cancer: a decade of progress.

  2002cited by this paper
• Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.

  2001cited by this paper
• K-ras and rho A mutations in malignant pleural effusion.

  2001cited by this paper
• K-ras codon 12 mutations may be detected in serum of patients suffering from adeno- and large cell lung carcinoma. A preliminary report.

  2001cited by this paper
• The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.

  2000cited by this paper
• Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA.

  2000cited by this paper
• Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.

  1999cited by this paper
• K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.

  1999cited by this paper
• Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours.

  1995cited by this paper
• Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis.

  1995cited by this paper
• Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.

  1994cited by this paper
• Epidemiology of lung cancer.

  1994cited by this paper
• Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique.

  1991cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper

• Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology

  2025cites this paper
• Circulating tumour DNA analysis for early detection of lung cancer: a systematic review

  2024cites this paper
• Conducting polymer composite-based biosensing materials for the diagnosis of lung cancer: A review.

  2023cites this paper
• Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors

  2023cites this paper
• Detection of KRAS mutation using plasma samples in non-small-cell lung cancer: a systematic review and meta-analysis

  2023influential citation
• Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications

  2023cites this paper
• Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives

  2022cites this paper
• Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

  2022cites this paper
• Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk

  2022cites this paper
• Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis

  2022cites this paper
• Argonaute integrated single-tube PCR system enables supersensitive detection of rare mutations

  2021cites this paper
• Calling Attention to the Role of Race-Driven Societal Determinants of Health on Aggressive Tumor Biology: A Focus on Black Americans.

  2021cites this paper
• Targeting Mutated KRAS Genes to Treat Solid Tumours

  2021cites this paper
• Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

  2021cites this paper
• Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer

  2021cites this paper
• Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy

  2021cites this paper
• Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response

  2020cites this paper
• The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer

  2020cites this paper
• Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.

  2020cites this paper
• La biopsia líquida en el diagnóstico y monitoreo de pacientes oncológicos: oportunidades y retos en Latinoamérica

  2020cites this paper
• Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer

  2020cites this paper
• Tumorspheres as an in vitro model for cancer stem-like cell characterization in non-small cell lung cancer. Prognostic implications

  2020cites this paper
• The emerging role of cell-free DNA as a molecular marker for cancer management

  2019cites this paper
• Cell-free DNA as Diagnostic Markers

  2019cites this paper
• Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.

  2019cites this paper
• The diagnostic value of circulating tumor cells and ctDna for gene mutations in lung cancer

  2019cites this paper
• The diagnostic value of circulating tumor cells and ctDna for gene mutations in lung cancer

  2019cites this paper
• Argonaute-mediated system for supersensitive and multiplexed detection of rare mutations

  2019cites this paper
• Use of circulating nucleic acids, metabolites, and proteins as clinical biomarkers for earlier prognosis and diagnosis of disease

  2019cites this paper
• The diagnostic value of circulating tumor cells and ctDna for gene mutations in lung cancer

  2019cites this paper
• Preclinical Evaluation Of Curcumin And Its Meriva Formulation For Non-Small Cell Lung Cancer Chemoprevention

  2019cites this paper
• Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.

  2019cites this paper
• The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer

  2019cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Fe–Au Nanoparticle‐Coupling for Ultrasensitive Detections of Circulating Tumor DNA

  2018cites this paper
• Clinical Interest of Circulating Tumor DNA in Oncology.

  2018cites this paper
• Circulating cell-free DNA for non-invasive cancer management.

  2018cites this paper
• The value of cell‐free DNA for molecular pathology

  2018cites this paper
• Targeting the RAS-dependent chemoresistance: The Warburg connection.

  2018cites this paper
• Genetic profiling of cancer with circulating tumor DNA analysis.

  2018cites this paper
• Unravelling lung cancer heterogeneity and associated therapeutic responses using in vivo and ex vivo model systems

  2018cites this paper
• Cell-Free DNA: An Overview of Sample Types and Isolation Procedures.

  2018cites this paper
• Potential clinical applications of circulating cell-free DNA in ovarian cancer patients

  2018cites this paper
• Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?

  2018cites this paper
• Molecular analysis of circulating cell-free DNA in lung cancer

  2017cites this paper
• The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis

  2017cites this paper
• Lung Cancer Biomarkers in Circulation

  2017cites this paper
• Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis

  2017cites this paper
• Liquid biopsies come of age: towards implementation of circulating tumour DNA

  2017cites this paper
• KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.

  2016cites this paper
• DNA Clutch Probes for Circulating Tumor DNA Analysis.

  2016cites this paper
• Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

  2016cites this paper
• Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease

  2016cites this paper
• Circulating biomarkers to monitor cancer progression and treatment

  2016cites this paper
• Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

  2016cites this paper
• KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies

  2016cites this paper
• Comparison of PNA clamping and direct sequencing for detecting KRAS mutations in matched tumour tissue, cell block, pleural effusion and serum from patients with malignant pleural effusion

  2015cites this paper
• Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?: A Report of the Association for Molecular Pathology.

  2015cites this paper
• Circulating DNA and Survival in Solid Tumors

  2015cites this paper
• [Potential of Cell-free Circulating DNA in Diagnosis of Cancer].

  2015cites this paper
• Potenciál volné cirkulující DNA v diagnostice

  2015cites this paper
• Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

  2015cites this paper
• Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

  2015cites this paper
• An electrochemical clamp assay for direct, rapid analysis of circulating nucleic acids in serum.

  2015cites this paper
• Lung Cancer Prediction Using Neural Network Ensemble with Histogram of Oriented Gradient Genomic Features

  2015cites this paper
• Pharmacodynamic Biomarkers: Falling Short of the Mark?

  2014cites this paper
• Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.

  2014cites this paper
• Optimized Library Prep for Cell-Free DNA from Human Plasma

  2014cites this paper
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

  2013cites this paper
• Biomarkers and biosensors for the early diagnosis of lung cancer

  2013cites this paper
• Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.

  2013cites this paper
• The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

  2013cites this paper
• The genetics and biology of KRAS in lung cancer

  2013cites this paper
• Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?

  2013cites this paper
• Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

  2013cites this paper
• Respiratory cytology in the era of molecular diagnostics: A review

  2012cites this paper
• Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer.

  2012cites this paper
• KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer

  2012cites this paper
• Marqueurs moléculaires prédictifs de réponse aux thérapies ciblées dans les cancers digestifs

  2012cites this paper
• Development of nanoparticle-modified sensor platform for cancer marker detection

  2012cites this paper
• The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.

  2011cites this paper
• Ras in cancer and developmental diseases.

  2011cites this paper
• Cell-free nucleic acids as biomarkers in cancer patients

  2011cites this paper
• Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer

  2010cites this paper
• DNA Biomarkers in the Diagnosis and Management of Cancer

  2010cites this paper
• Circulating DNA as a Biomarker for Early Detection of Cancer: A Brief Update with an Emphasis on Lung Cancer~!2010-06-09~!2010-08-03~!2010-09-06~!

  2010cites this paper
• Analyzing the Impact of EGFR-induced c-Met Phosphorylation in Non-Small Cell Lung Cancer

  2010cites this paper
• Bedeutung der Histologie für die Therapie des fortgeschrittenen, nicht-kleinzelligen Bronchuskarzinoms

  2010cites this paper
• Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation: Report of Toxicity and Evaluation of Circulating K-ras as a Potential Biomarker of Response to Therapy

  2009cites this paper
• KRAS et cancer colorectal : un pas de géant vers la médecine personnalisée

  2009cites this paper
• A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

  2009cites this paper
• Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients?

  2009cites this paper
• The status of KRAS mutations in patients with non-small cell lung cancers from mainland China.

  2009cites this paper
• EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

  2009cites this paper
• K-RAS mutation in the screening, prognosis and treatment of cancer.

  2009cites this paper
• Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

  2009cites this paper
• KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.

  2009cites this paper
• Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.

  2008cites this paper